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STEVENS JOHNSON SYNDROME
Stevens Johnson Syndrome: How Diagnosis Impacts Disease Course
Stevens Johnson syndrome (SJS) is a rare, potentially life threatening, severe adverse
drug reaction involving the skin and mucous membranes. SJS affects only one to five patients
per million annually (Rehmus, n.d.), therefore providing a challenge to medical providers for
timely diagnosis and appropriate treatment. Even after the patient battles SJS for their lives,
their struggle is long from over. Complications of SJS include living with scars and
complications related to eye injury and corneal tears that their bodies sustained from this rare
condition. By facilitating the knowledge base of the Advanced Practice Nurse (APN), an
expedient diagnosis of SJS may be achieved in order to prevent delay in diagnosis that can
increase complications from infections and mortality.
Background
SJS was first noted in 1922 as an acute mucocutaneous syndrome in which cell death
causes the epidermis to separate from the dermis (Harr & French, 2010). Two American
physicians named Stevens and Johnson first noted this syndrome in two young boys with
symptoms “described as an acute mucocutaneous syndrome characterized by severe purulent
conjunctivitis and severe stomatitis with extensive mucosal necrosis” (Naveen, Pai, Rai, &
Athanikar, 2013, p. 80). Presenting symptoms typically include fever, sore throat, and fatigue
that can be misdiagnosed and treated with a course of antibiotics, which could possibly continue
or worsen the condition. Any mucosal membrane has the potential of being affected. SJS has
been linked to agents including NSAIDS (non-steroid anti-inflammatory drugs), allopurinol,
phenytoin, carbamazepine, barbiturates, anticonvulsants, and sulfa antibiotics, but almost any
medication can be a cause (DeClerck, Jhun, Bright & Herbert, 2015). Individuals who
experience SJS have usually completed a course of antibiotics or drug therapy and present with a
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rash, fever, lesions in the mouth, and/or eye irritation. Unlike typical allergic drug reactions, the
presentation of SJS is delayed by one to four weeks after the initiation of the medication.
SJS and Toxic Epidermal Necrolysis (TEN) present as severe mucosal erosions with
widespread erythematous, cutaneous macules or atypical targets (Ghislain & Roujeau,
2002), SJS and TEN are considered to be the same syndrome, but on opposite ends of the
spectrum. SJS differs from TEN by the degree of body surface involvement. In SJS the
detachment of the epidermis is less than 10%, with the SJS/TEN overlap skin detachment range
is 10-30%, and more than 30% of body surface involvement happens with TEN. When there is
more skin surface involvement there is a corresponding higher mortality rate. The mortality rate
for SJS is 5-15% and 30-35% for TEN (Ghislain & Roujeau, 2002). Risk factors for both SJS
and TEN are increased when there is continued exposure to the predisposing factor, an
autoimmune disorder, or a human leukocyte antigen (HLA)-linked genetic susceptibility. This
HLA-linked factor affects individuals of Asian descent and makes them more susceptible to SJS.
“The genetic variations most strongly associated with SJS/TEN occur in the HLA-B gene”
(Genetics Home Reference, n.d.). The HLA complex helps the body to tell the difference
between proteins the body makes and proteins that are foreign substances like those made by
viruses and bacteria. When the body has a reaction to drugs, a substance called granulysin is
released by the immune cells cytotoxic T cells and natural killer (NK) cells which destroys skin
and mucous membrane cells (Genetics Home Reference, n.d.). When the cells are destroyed or
die that is what causes the peeling and blistering skin associated with SJS/TEN patients.
Research Question
Due to SJS being a rare reaction, it is crucial to provide primary and emergency care
providers with the appropriate tools to aid in early recognition of SJS symptoms. Early
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recognition and subsequent diagnosis along with removal of the offending pharmacological
agent will assist in minimizing mucocutaneous damage. Many SJS and TEN patients present
with skin lesions that are inflamed and resemble partial thickness burns or scalded skin.
Primarily, the goal of treatment is to reduce the devastating impact of SJS while minimizing
avoidable long-term effects of therapy. Does early diagnosis shorten the disease course in
patients with SJS? Ultimately, a strong working knowledge by the Advanced Practice Nurse
regarding SJS is imperative in order to reduce additional risks and facilitate a return of
homeostasis by the patient.
Literature Review
The focus of this literature review is to provide information regarding how diagnosis
impacts the disease course in patients with SJS and to facilitate understanding regarding current
treatment plans. Even though SJS and TEN affect only a small number of individuals, it is
important for health care providers to understand what can be done to improve the process in
diagnosing these individuals, improve the recovery time and eliminate any lasting injury from
the disease process. The following eight literature reviews attempt to determine what current
evidence shows regarding how diagnosis from time of symptom onset impacts the disease
process and additional long-term effects from SJS.
One study by Naveen, Pai, Rai & Athanikar supported that “early identification of the
drug will help in prompt withdrawal of the drug thus reducing mortality and morbidity among
the patients with SJS/TEN” (Naveen, et al., 2013, p. 80). A focus of the study was to help those
prescribing and treating patients to use caution when prescribing medications and to understand
the risk of the drugs that cause the life threatening reactions. In this retrospective analysis, antiepileptics, antibiotics, antipsychotics, analgesics and antiretrovirals were the causal drugs. More
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patients were affected by antiepileptics in this study (50%) followed by antibiotics. The drug
that had a higher morbidity and mortality rate was ofloxacin instead of the anti-epileptic that had
a higher usage rate. The drug ofloxacin had a longer recovery time of 9.6 days and
anticonvulsants had 6 days. The study emphasized drugs that were the possible trigger of
SJS/TEN.
With polypharmacy becoming more common it is important to find the culprit drugs
early to ensure removal is performed accurately and to avoid removing effective drug
therapies. The importance of this study will help APNs and physicians to understand which
drugs could be possible triggers of SJS/TEN and what treatment plans could be
effective. Another aspect that came out of this study was the use of steroids and how steroids
could affect the outcomes of SJS/TEN if given early in the treatment process. The limitations of
the study are that it had a small sample size of 22 individuals, 14 males and 8 females. The age
group that was most affected in this study was 20-40 years old, but the mean age in other studies
varied, so age could play a factor in reaction times of the offending drugs.
In a multicenteric, retrospective study completed by Barvaliya, Sanmukhani, Patel,
Paliwal, Shah, & Tripathi (2011) data for patients with SJS and TEN were evaluated to “find out
the proportion of individual drugs involved, major complications, and cost of management”
(p.116) associated with these diagnoses. Of the 32 cases included, antimicrobials were the most
common causative drug followed by nonsteroidal anti-inflammatory drugs (NSAIDS) and
antiepileptic drugs. Secondary infections were the most common complication and the cost of
management was higher in patients with a SJS/TEN overlap or TEN diagnoses in comparison to
other adverse drug reactions (ADR’s) while SJS remained similar in cost. Barvaliya et al. (2011)
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also compared SCORTEN scores with actual patient mortality. The research findings showed a
higher mortality rate with a higher SCORTEN score.
Limitations noted within this study include 13 patients with co-existing HIV and a small
sample size. Patients with co-existing HIV decrease generalizability of the findings while
enhancing the knowledge of potential causes of SJS in this vulnerable population. The findings
increase knowledge concerning the most common causative drugs in patients with SJS and TEN
for the stated population and continue to validate the value of SCORTEN for predicting
mortality.
A small study by Mehta, Prajapati, Mittal, Joshi, Sheth, Patel, & Goyal (2009) examined
the association of human leucocyte antigen (HLA)-B*1502 allele and carbamazepine
induced SJS in Indian patients. This research was based on the strong association between the
HLA-B*1502 allele and carbamazepine induced SJS in Han Chinese patients. Previous research
suggests that carbamazepine induced SJS and its association with the HLA-B*1502 allele is
ethnicity specific for Asian patients.
Carbamazepine is a commonly prescribed antiepileptic in India and is responsible for
many cases of SJS/TEN in Indian patients. Mehta et al. (2009) found that six of the eight Indian
patients with carbamazepine induced SJS had the HLA-B*1502 gene, while none of the ten
patients in the control group had the gene. The association between the HLA-B*1502 gene is
not as strong in Indian patients in comparison to Han Chinese patients, but this research does
show a significant association (P=0.0014) between the HLA-B*1502 allele and carbamazepine
induced SJS in Indian patients.
The main limitation within this study was the small sample size. The findings suggest the
need for more research concerning genetic susceptibility and its association with the
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development of SJS/TEN. This research promotes knowledge concerning potential causes of
SJS in Indian patients which is useful for any health care provider caring for an ethnically
diverse group of patients. All providers should have an understanding of genetic susceptibility
when prescribing medications for ethnically diverse patients.
Bansal, Garg, Sardana, and Sarkar (2015) completed an analysis on the predictive value
and accuracy of the SCORe of Toxic Epidermal Necrolysis (SCORTEN) scale in predicting
disease severity and patient prognosis. SCORTEN was developed and validated in 2000 by
Bastuji-Garin et al. as a way for health care providers to predict disease severity and mortality
based on seven parameters in patients with SJS and TEN (Bansal et al., 2015).
This study evaluated SCORTEN values on days 1, 3, and 5 following diagnosis and
compared them to actual mortality. Of the 60 patients in the study, the discriminative ability of
SCORTEN values was appropriate at each time point with day 5 being the most significant (P<
0.001). Bansal et al. (2015) also reported that of the SCORTEN parameters only heart rate,
blood urea, and serum bicarb were statistically significant (P< 0.05) concerning mortality. Other
risk factors including delayed hospitalization, hypernatremia, and skin colonization were
evaluated and did not show statistical significance with patient mortality. The researchers shared
how the first eight to twelve days of SJS/TEN is considered the acute phase during which the
disease progresses. During this phase, time of symptom onset influences SCORTEN’s predictive
ability greater than length of hospital stay. Ethnicity must also be considered when evaluating
patients with SJS/TEN due to the noted differences in causative factors, genetics and
comorbidities. All 60 patients received conservative treatment which included “withdrawal of
the causative agent, fluid replacement, nutritional support, temperature regulation, provision of
daily dressings and prophylactic antibiotics” (Bansal et al, 2015, p. e19). The mortality rate of
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16.7% noted in this study presents conservative treatment, as previously described, as a valid
option for SJS/TEN.
Limitations noted in this research included a participant mean age of 23.3 years (Bansal
et al.) while the original study, completed by Bastuji-Garin et al., had a mean age of 42.3
years. With the SJS and TEN being a rare reaction, 60 participants is a large number therefore
strengthening the validity of this study. SCORTEN’s predictive value remains valid and
continues to be a useful tool for providers when caring for patients with SJS.
A large cohort study of 513 patients with SJS or TEN from six countries Austria,
France, Germany, Israel, Italy, and the Netherlands were enrolled in EuroSCAR from a network
of about 1800 hospitals. This is a registry of a multinational collaborative research team that was
established in 1988 to study severe cutaneous adverse reactions (SCAR), recently changed to
RegiSCAR-group. Collaborating members include specialists in dermatology, epidemiology,
genealogy and immunology where they studied three different varieties of SCAR, which include
SJS/TEN. The majority of enrolled patients (80%) were from France and Germany. There were
379 patients that had confirmed diagnosis of SJS or TEN who developed a reaction outside the
hospital. The patients were classified by any treatment after hospitalization that used systemic
corticosteroids, intravenous immunoglobulin (IVIG) or immunosuppressive agents. The study
analyzed differences in outcomes from three different drug treatment plans in relation to earlier
and later treatment of a combination of IVIG only, IVIG and corticosteroids or corticosteroids
only. The research supports that age is an important factor in mortality with the death rate being
lower in children than adults. Other factors in this study that contributed to a “poor prognosis”,
were related to new diagnosis of cancer or other possible underlying diseases like
“hyperglycemia, elevated urea, and decreased bicarbonates” (Schneck et al., 2007, p. 33). The
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SCORTEN scale which is a predictor of mortality and severity of illness was not used in this
study because not enough data were collected in the EuroSCAR study. There were 134 patients
with SJS (35%), 136 patients with SJS/TEN overlap (36%), and 109 patients with TEN
(29%). Authors concluded that the mortality rate was 21% or 81 patients who did not survive
their disease process. There was a strong correlation of death risk related to the patient’s age and
severity of disease.
The limitation of this study were differences in two main countries, France and Germany,
and there were no significant benefit from any one medication treatment, neither was there any
difference in outcomes related to early or late treatment. The study pointed out that there were
many challenging aspects to control in this study to get a definitive answer on treatment plans of
corticosteroid and IVIG medication benefits. Another study would be necessary to observe a
uniform treatment plan especially studying a low or high dose regimen to provide a better
outcome analysis and the effects on the disease course of SJS/TEN.
The importance of the study was the finding that no treatment modality was better in
treating SJS/TEN, than simple early detection and removal of the offending drug and starting
supportive care early. The strengths of the study include a well-defined population, the largest
ever studied. Patients were assessed by an expert committee and information was obtained in a
way to assure correct classification of the disease stage.
A study examined by Kardaun and Jonkman (2007) found Dexamethasone Pulse Therapy
(DPT), if given early in the treatment process, can possibly reduce the mortality risk. DPT is the
administration of large doses of drugs in an intermittent manner to enhance the therapeutic effect
and reduce side effects (“What is Pulse Therapy, n.d.). DPT was started early and contributed to
a relatively quick stabilization and healing, may even have halted the process of apoptosis or cell
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death. If DPT is given for longer periods of time it increases the risk of infection. On the other
hand corticosteroids usually are not given because it can delay wound healing and cause sepsis.
DPT is used with corticosteroids in severe, sometimes autoimmune, diseases. The only
definitive way to diagnose SJS/TEN is to take a skin biopsy that verifies sub epidermal
involvement. In this study, DPT treatment was started as soon as a definitive diagnosis was
made.
The strength of the study showed that using DPT early in the disease course could
possibly stop the cell damage and could reduce mortality in SJS/TEN patients. The limitations
were a small sample size of 12 patients over a 10 year period and it was difficult to show
statistical relevance because of the small number of patients.
Another retrospective study of treating patients with IVIG therapy was completed by
Gravante, Delogu, Marianetti, Trombetta, Esposito and Montone in 2007. The study consisted of
understanding how late referral to their center increased the risk of mortality in patients because
IVIG therapy treatment was not started early and the risk of infection increased. There was a 10
day delay in referral in starting the IVIG therapy and supportive care. “This delay of referral
increased mortality probability of 416.5 times, with the absence of IVIG therapy of 67.5 times
and more than 2-types of bacteria 84 times” (Gravante, et al., 2007, p. 121). Late referral and
total body surface area of detached skin are two factors that contributed to an increased death
rate. Out of 35 patients that had an initial diagnosis of TEN, 32 patients were included in this
study. The 32 patients that were evaluated, there was one case of SJS and seven patients with
SJS/TEN overlap. This made up 25% with SJS involvement and a total mortality rate of 34.4%
which is 11 out of 32 patients studied (Gravante, et al., 2007).
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The limitations in this retrospective study show that it is difficult to determine how sick
patients were at time of referral. This could have an impact on mortality rates and what the
treatment regimens were at the time of the study. Another limitation was the small sample
size. The importance of the study showed that septicemia played an important role in mortality,
and if there were more than three different bacteria present during hospitalization than this
increased the risk of death for patients. This study showed an encouraging outcome of giving
IVIG even if there is late referral to treatment. Further studies are recommended to understand
current treatment modalities and the specific effect on IVIG therapy. Even though IVIG therapy
is not well established for SJS/TEN in this study, the delay in introducing specific
immunoglobulin-blocking therapy and specific support therapy contributed to an increased risk
of death.
A study completed by Singh, Chatterjee, and Verma (2013) compared the use of
cyclosporine versus steroids for treatment of patients with SJS and TEN. The researchers
reported a significant reduction in the amount of time to the arrest of progression of SJS/TEN (P
= 0.04282), total re-epithelization time (P = 0.009956) and hospitalization stay (P = 0.02597) in
those treated with cyclosporine in comparison to those treated with corticosteroids. There were
no statistically significant differences noted between the cyclosporine and corticosteroid groups
concerning age, total body surface area (TBSA) and onset of disease to admission time. Singh et
al. also reported on other studies showing that early withdrawal of the causative drug positively
influenced prognosis and causative drugs with a long half-life increase the risk of
mortality. Identification of the causative drug can be challenging in patients receiving multiple
medications that have the potential to cause SJS/TEN.
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This research was conducted over a one year time span on eleven patients who has SJS or
TEN. Once again the number of participants is small for research purposes, but when combined
with other studies, the evidence does promote the use of cyclosporine in uncomplicated cases of
SJS and TEN. Timely diagnosis from onset of symptoms and removal of the causal agent
combined with cyclosporine treatment provides hope for providers who aim to decrease
mortality in patients with SJS and TEN.
Recommendations
One recommendation to practice is to have a better understanding of how certain
medications are a leading cause of SJS and TEN in over 75% of cases affecting both adults and
children. When patients present with symptoms resembling SJS, a thorough drug history and
identification of any causative medications must be identified. The causative agent should be
eliminated and supportive care started immediately following diagnosis. If the reaction resulted
from a sulfonamide, early diagnosis will provide avoidance of drugs that have a sulfa-base, such
as silver sulfadiazine ointment, which is commonly used for burn patients. The Advanced
Practice Nurse must have a strong working knowledge of SJS/TEN symptoms and causative
medications to reduce additional risks and facilitate early treatment plans for the patient.
Conclusion
The reviewed literature consistently stated that apart from intensive supportive therapy,
there is no accepted guideline for treatment or standard practice that exists besides supportive
care. Most of the literature states that larger cohorts need to be studied and that there still is a
lack of information regarding SJS/TEN and the benefits of IVIG, cyclosporine and corticosteroid
treatment. When there is a delay in early diagnosis, there is an increased risk in mortality because
the causative drug is still triggering injury and supportive care has not been initiated.
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In order to advance knowledge about SJS/TEN and prevent delay in diagnosis, it is
important to have concise drug information given to all physicians and primary care
providers. Adverse drug reactions are the leading cause of SJS and TEN and a multidisciplinary
approach is needed to manage any complications of the syndrome. More than 100 drugs are
associated with SJS/TEN, and an improved system of warnings is needed in drug dictionaries
regarding any associated risk. It is important for health care providers to understand what can be
done to improve the process of diagnosing these individuals, shorten their disease course and
eliminate lasting injury from the disease process.
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